novo nordisk glp-1 medications justifies reasoning behind failed Alzheimer's trials GLP-1s for Alzheimer's: Novo Nordisk

Speak to your GP about contraception options before starting any GLP-1 medication

4 r 4.9% ARR reported at 3 years in prespecified supplementary analysis

With growing interest in medications like semaglutide, patients are increasingly looking for ways to access these treatments in more convenient, tolerable formats

This study aimed to evaluate the effectiveness and safety of orforglipron, a nonpeptide, oral GLP-1 receptor agonist, for weight loss in adults with obesity

Compared with long-acting insulin, GLP-1RA therapy reduces the risk of composite liver disease (cirrhosis or hepatocellular carcinoma) in patients with type 2 diabetes by 44%, with a 41% reduction in cirrhosis risk and a 53% reduction in hepatocellular carcinoma risk